EU/3/16/1752
About
On 14 October 2016, orphan designation (EU/3/16/1752) was granted by the European Commission to Pfizer Limited, United Kingdom, for human monoclonal IgG1 antibody against tissue factor pathway (also known as PF-06741086) for the treatment of haemophilia A.
The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in November 2018.
Key facts
Active substance |
Human monoclonal IgG1 antibody against tissue factor pathway inhibitor
|
Disease / condition |
Treatment of haemophilia A
|
Date of first decision |
14/10/2016
|
Outcome |
Positive
|
EU designation number |
EU/3/16/1752
|
Sponsor's contact details
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
E-mail: orphan_enquiries@pfizer.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.